摘要
目的观察多西他赛联合FOLFOX方案治疗进展期胃癌的疗效及不良反应。方法对32例进展期胃癌行多西他赛联合FOLFOX方案化疗,3周为1周期,完成2个周期后评价疗效。结果化疗总有效率37.5%,中位疾病进展时间6.3个月,中位生存期10.4个月。不良反应以骨髓抑制、胃肠道反应和静脉炎为主。结论多西他赛联合FOLFOX方案治疗进展期胃癌有较好的疗效,毒副作用可以耐受,可作为进展期胃癌一线治疗方案。
Objective To evaluate the efficacy and toxicity of Docetaxel（DTX） combined with FOLFOX in treating patients with advanced gastric carcinoma.Methods Thirty-two patients were treated with Docetaxel and FOLFOX regimen,（1 cycle=every 3 weeks）.Tumor assessment was done after 2 cycles.Results The overall response rate was 37.5%,and the median TTP was 6.3 months.Median survival time was 10.4 months.The main toxicity was nyelosuppression,gastroin-testinal tract reaction and phlebitis.Conclusion Docetaxel combined with FOLFOX regimen is active and is less toxic and the regimen can be applied to the first line chemotherapy.
出处
《实用临床医药杂志》
CAS
2011年第9期59-61,共3页
Journal of Clinical Medicine in Practice
关键词
多西他赛
FOLFOX
进展期胃癌
Docetaxel
FOLFOX
chemotherap
advanced gastric carcinoma
